- Home
- STSS vs INDP Comparison
STSS vs INDP Comparison
Compare STSS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- INDP
- Stock Information
- Founded
- STSS 2017
- INDP 2000
- Country
- STSS United States
- INDP United States
- Employees
- STSS N/A
- INDP N/A
- Industry
- STSS Medical/Dental Instruments
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- INDP Health Care
- Exchange
- STSS Nasdaq
- INDP Nasdaq
- Market Cap
- STSS 5.5M
- INDP 5.0M
- IPO Year
- STSS 2022
- INDP N/A
- Fundamental
- Price
- STSS $5.53
- INDP $11.12
- Analyst Decision
- STSS
- INDP Strong Buy
- Analyst Count
- STSS 0
- INDP 2
- Target Price
- STSS N/A
- INDP $8.50
- AVG Volume (30 Days)
- STSS 2.7M
- INDP 689.8K
- Earning Date
- STSS 08-13-2025
- INDP 08-11-2025
- Dividend Yield
- STSS N/A
- INDP N/A
- EPS Growth
- STSS N/A
- INDP N/A
- EPS
- STSS N/A
- INDP N/A
- Revenue
- STSS N/A
- INDP N/A
- Revenue This Year
- STSS N/A
- INDP N/A
- Revenue Next Year
- STSS N/A
- INDP N/A
- P/E Ratio
- STSS N/A
- INDP N/A
- Revenue Growth
- STSS N/A
- INDP N/A
- 52 Week Low
- STSS $3.36
- INDP $7.56
- 52 Week High
- STSS $2,224.20
- INDP $67.48
- Technical
- Relative Strength Index (RSI)
- STSS 43.41
- INDP 98.13
- Support Level
- STSS $5.15
- INDP $0.31
- Resistance Level
- STSS $5.83
- INDP $0.71
- Average True Range (ATR)
- STSS 0.46
- INDP 0.07
- MACD
- STSS 0.41
- INDP 0.77
- Stochastic Oscillator
- STSS 32.28
- INDP 99.09
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.